Streetbeat News

Earnings

FEMY

Femasys reported a Q2 2024 EPS of $(0.21).

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 12:42 pm

EWTX

Edgewise Therapeutics (NASDAQ:EWTX) reported a Q2 EPS of $(0.34), beating the analyst estimate of $(0.36) by 5.56%. This result is unchanged from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 12:42 pm

BKTI

BK Technologies shares are trading higher following the company's report of a year-over-year increase in Q2 revenue.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 12:42 pm

BMBL

Bumble Inc. (NASDAQ:BMBL) reported worse-than-expected Q2 revenue results, leading to multiple analysts downgrading their ratings and slashing price targets. Despite a slight rise in share price, the outlook remains cautious.

Portfolio Pulse from Avi Kapoor

August 08, 2024 | 12:41 pm

XTNT

Xtant Medical Holdings reported its Q2 2024 financial results with a GAAP EPS of $(0.03), missing the estimate of $(0.02). However, the company reported sales of $29.943 million, beating the estimate of $28.700 million.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 12:41 pm

RLYB

Rallybio (NASDAQ:RLYB) reported Q2 earnings per share (EPS) of $(0.37), missing the analyst consensus estimate of $(0.33) by 12.12%. This represents a 19.57% improvement over the $(0.46) per share loss from the same period last year. The company also reported $299.00 thousand in sales for the quarter.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 12:40 pm

RLYB

Rallybio (NASDAQ:RLYB) reported a Q2 EPS of $(0.37), missing the analyst consensus estimate of $(0.33) by 12.12%. This represents a 19.57% improvement over the $(0.46) loss per share from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 12:40 pm

IRON

Disc Medicine (NASDAQ:IRON) reported a Q2 EPS loss of $(1.03), beating the analyst estimate of $(1.11) by 7.21%. This represents a 39.19% increase in losses compared to $(0.74) per share from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 12:39 pm

HBIO

Harvard Bioscience has revised its FY24 revenue outlook to $97M - $102M, down from the previous estimate of $111.95M, due to delayed market recovery. The company expects a full-year gross margin of 59% to 60% and an adjusted EBITDA margin in the high single digits.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 12:39 pm

QTI

QT Imaging reported Q2 2024 revenue of $1.714 million and an EPS of $(0.30).

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 12:39 pm